Managing CAD and Stage 3a CKD with Sleep Apnea

Introduction to Management

The American Heart Association recommends ambulatory blood pressure monitoring for patients with OSA, as nocturnal hypertension is common and may contribute to cardiorenal syndrome 1

The European Society of Cardiology recommends intensive medical therapy as the initial approach for patients with stable CAD and CKD stage 3a, rather than rushing to invasive procedures 2, 3
The European Society of Cardiology recommends low-dose aspirin 75-100 mg daily for secondary prevention in patients with established CAD 2, 3
The American College of Cardiology recommends high-intensity statin therapy to reduce LDL-C by ≥50% or achieve LDL-C <1.4 mmol/L (55 mg/dL) for patients with CAD and CKD 5, 4
The European Society of Cardiology recommends ACE inhibitor or ARB as first-line therapy for patients with CAD and CKD stage 3a 5, 7, 6
The European Society of Cardiology recommends SGLT2 inhibitors, such as empagliflozin, canagliflozin, or dapagliflozin, to reduce CKD progression and cardiovascular events in patients with CAD and CKD stage 3a 2, 7, 6

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend continuing ACE inhibitor/ARB therapy as the cornerstone of slowing CKD progression, especially if patients have albuminuria 2, 8
The European Society of Cardiology recommends limiting protein intake to 0.8 g/kg body weight/day to slow CKD progression 8
The American Heart Association recommends a Mediterranean-style, plant-based diet to reduce both cardiovascular and kidney disease risk 2, 8

The American College of Cardiology recommends prioritizing an invasive strategy if patients have acute or unstable coronary symptoms, unacceptable angina despite optimal medical therapy, left ventricular systolic dysfunction attributable to ischemia, or left main disease on imaging 2, 4

The European Society of Cardiology recommends demanding iso-osmolar contrast agents and minimizing volume to prevent contrast-induced nephropathy in patients undergoing coronary angiography 7, 9
The American Heart Association recommends ensuring adequate hydration protocols and monitoring eGFR to prevent contrast-induced kidney injury 9

The European Society of Cardiology recommends aerobic exercise 150-300 minutes/week of moderate intensity (or 75-150 minutes vigorous) to reduce cardiovascular risk 4, 8
The American Heart Association recommends reducing sedentary time, restricting sodium, limiting alcohol, meats, and high-fructose corn syrup to reduce cardiovascular and kidney disease risk 4, 8, 6, 2